The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

Age-related macular degeneration (AMD ... As of 2023, the only FDA-approved treatments for dry AMD are two injectable drugs. These treatments are constrained by potential complications from ...

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration ... the sound of a voice to recognise who was there.

In the last 20 years, there have been rapid advances in the treatment options for myopic ... it is possible that patients with myopic macular degeneration complicated by CNV may benefit from ...

Volunteers are needed to help run a leading sight loss charity support group, which supports people affected by macular ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.